Lonza Group AG - Asset Resilience Ratio
Lonza Group AG (LONN) has an Asset Resilience Ratio of 3.04% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Lonza Group AG to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Lonza Group AG's Asset Resilience Ratio has changed over time. See Lonza Group AG balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Lonza Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Lonza Group AG (LONN) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF600.00 Million | 3.04% |
| Total Liquid Assets | CHF600.00 Million | 3.04% |
Asset Resilience Insights
- Limited Liquidity: Lonza Group AG maintains only 3.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lonza Group AG Industry Peers by Asset Resilience Ratio
Compare Lonza Group AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
Annual Asset Resilience Ratio for Lonza Group AG (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Lonza Group AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.54% | CHF481.00 Million ≈ $608.11 Million |
CHF18.97 Billion ≈ $23.98 Billion |
-3.98pp |
| 2024-12-31 | 6.51% | CHF1.28 Billion ≈ $1.62 Billion |
CHF19.73 Billion ≈ $24.95 Billion |
-1.82pp |
| 2023-12-31 | 8.33% | CHF1.40 Billion ≈ $1.77 Billion |
CHF16.85 Billion ≈ $21.30 Billion |
-3.15pp |
| 2022-12-31 | 11.48% | CHF1.99 Billion ≈ $2.52 Billion |
CHF17.36 Billion ≈ $21.94 Billion |
-2.07pp |
| 2021-12-31 | 13.55% | CHF2.23 Billion ≈ $2.82 Billion |
CHF16.46 Billion ≈ $20.81 Billion |
+13.84pp |
| 2020-12-31 | -0.29% | CHF-43.00 Million ≈ $-54.36 Million |
CHF14.62 Billion ≈ $18.49 Billion |
-0.03pp |
| 2019-12-31 | -0.27% | CHF-37.00 Million ≈ $-46.78 Million |
CHF13.84 Billion ≈ $17.50 Billion |
-0.71pp |
| 2018-12-31 | 0.44% | CHF61.00 Million ≈ $77.12 Million |
CHF13.92 Billion ≈ $17.60 Billion |
+0.23pp |
| 2017-12-31 | 0.21% | CHF29.00 Million ≈ $36.66 Million |
CHF13.83 Billion ≈ $17.49 Billion |
-0.73pp |
| 2016-12-31 | 0.94% | CHF64.00 Million ≈ $80.91 Million |
CHF6.83 Billion ≈ $8.63 Billion |
+0.89pp |
| 2015-12-31 | 0.05% | CHF3.00 Million ≈ $3.79 Million |
CHF6.25 Billion ≈ $7.90 Billion |
-0.09pp |
| 2014-12-31 | 0.14% | CHF9.00 Million ≈ $11.38 Million |
CHF6.44 Billion ≈ $8.14 Billion |
-0.27pp |
| 2013-12-31 | 0.41% | CHF26.00 Million ≈ $32.87 Million |
CHF6.37 Billion ≈ $8.06 Billion |
+1.58pp |
| 2012-12-31 | -1.17% | CHF-83.00 Million ≈ $-104.93 Million |
CHF7.10 Billion ≈ $8.98 Billion |
-0.37pp |
| 2011-12-31 | -0.80% | CHF-56.00 Million ≈ $-70.80 Million |
CHF7.02 Billion ≈ $8.88 Billion |
-0.82pp |
| 2009-12-31 | 0.02% | CHF1.00 Million ≈ $1.26 Million |
CHF4.94 Billion ≈ $6.25 Billion |
-0.06pp |
| 2008-12-31 | 0.08% | CHF4.00 Million ≈ $5.06 Million |
CHF4.93 Billion ≈ $6.24 Billion |
+0.65pp |
| 2007-12-31 | -0.57% | CHF-28.00 Million ≈ $-35.40 Million |
CHF4.95 Billion ≈ $6.26 Billion |
-0.26pp |
| 2006-12-31 | -0.31% | CHF-12.00 Million ≈ $-15.17 Million |
CHF3.91 Billion ≈ $4.95 Billion |
-0.03pp |
| 2005-12-31 | -0.28% | CHF-12.00 Million ≈ $-15.17 Million |
CHF4.33 Billion ≈ $5.48 Billion |
+0.05pp |
| 2004-12-31 | -0.33% | CHF-11.00 Million ≈ $-13.91 Million |
CHF3.34 Billion ≈ $4.22 Billion |
-- |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biol… Read more